|
|
|
|
Cangene's Hepatitis B product approved by European Commission
TORONTO and WINNIPEG, March 17 /CNW/ - Cangene Corporation today reports that it has received European Commission approval to market Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin), indicated for immunoprophylaxis of hepatitis B.
|
|
|
China works to stamp out discrimination against Hepatitis B carriers
Wang Huayang has experienced three unforgettable health checks so far -- one that first found him infected with Hepatitis B virus (HBV) and two others that confirmed his disease and made him ineligible for two hard-earned jobs within eight months...
|
|
|
China works to stamp out discrimination against Hepatitis B carriers
Wang Huayang has experienced three unforgettable health checks so far -- one that first found him infected with Hepatitis B virus (HBV) and two others that confirmed his disease and made him ineligible for two hard-earned jobs within eight months...
|
|
|
China works to stamp out discrimination against Hepatitis B carriers
Wang Huayang has experienced three unforgettable health checks so far -- one that first found him infected with Hepatitis B virus (HBV) and two others that confirmed his disease and made him ineligible for two hard-earned jobs within eight months...
|
|
|
Hepatitis B Virus - Researchers from University of Massachusetts provide details of new studies and findings i
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Hepatitis B Virus Researchers from University of Massachusetts...
|
|
|
Host Heat-Stress Cognate 70 as a Potential Drug Target against Drug-Resistance in Hepatitis B Virus [Article]
Host Heat-Stress Cognate 70 as a Potential Drug Target against Drug-Resistance in Hepatitis B Virus Yu-Ping Wang, Fei Liu, Hong-Wei He, Yan-Xin Han, Zhong-Gan Peng, Bao-Wei Li, Xue-Fu You, Dan-Qing Song, Zuo-Rong Li, Li-Yan Yu, Shan Cen, Bin Hong,...
|
|
|
Virologic and Clinical Outcomes of Hepatitis B Virus Infection in HIV-HBV Coinfected Transplant Recipients
Liver transplantation (LT) is the treatment of choice for end-stage liver disease, but is controversial in patients with human immunodeficiency virus (HIV) infection.Using a prospective cohort of HIV-hepatitis B virus (HBV) coinfected patients...
|
|
|
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus
Jnl of Viral Hepatitis Feb 2010 A.Tamori 1 , M. Enomoto 1 , S. Kobayashi 1 , S. Iwai 1 , H. Morikawa 1 , H. Sakaguchi 1 , D. Habu 2 , S. Shiomi 3 , Y. Imanishi 4 and N. Kawada 1 1 Department of Hepatology, Osaka City University...
|
|
|
Idera Pharmaceuticals to Present IMO-2125 Abstracts at EASL Annual Meeting
Idera Pharmaceuticals, Inc.has announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna,...
|
|
|
Idera Pharmaceuticals to Present IMO-2125 Abstracts at EASL Annua...
Company: Idera Pharmaceuticals Inc (IDRA) Idera Pharmaceuticals, Inc.has announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association for the...
|
|
|
Immunotherapy Markedly Increases the Effectiveness of Antimicrobial Therapy for Treatment of Burkholderia pseudomallei Infection [Article]
Immunotherapy Markedly Increases the Effectiveness of Antimicrobial Therapy for Treatment of Burkholderia pseudomallei Infection Katie L.Propst, Ryan M. Troyer, Lisa M. Kellihan, Herbert P. Schweizer, and Steven W. Dow* From the Department of...
|
|
|
Dr. Andy: Infants should get Hepatitis B vaccination
While the benefits of Hepatitis B vaccinations have been proven, that has not kept it from being part of the general debate over pediatric vaccinations.Since being introduced into the routine pediatric vaccination schedule in 1991, the rate of ...
|
|
|
Reportlinker Adds Disease and Therapy Review: Hepatitis B
Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0183446/Disease-and-Therapy-Review-Hepatitis-B.html Abstract The Hepatitis B Disease and Therapy Review provides an overview of the disease and...
|
|
|
NHVR: Increased funding needed for viral hepatitis screening, intervention
WASHINGTON (Mar.19) Systemic underfunding at the Centers for Disease Control and Preventions Division of Viral Hepatitis puts the health of millions of Americans with viral hepatitis at risk, a group of organizations focused on the disease said this...
|
|
|
Acupuncture can Transmit Serious Diseases Like HIV, Hepatitis
Alternative Medicine News Font Size Acupuncture treatment may lead to transmission of bacterial infections, hepatitis B and C, and even HIV, health experts have warned.Microbiologists at the University of Hong Kong insist that use of contaminated...
|
|
|
Spontaneous Clearance and Successful Treatment of Hepatitis C Linked to Better CD4 Cell Recovery
Numerous studies have shown that tend to experience more rapid liver disease progression than individuals with HCV alone, but the effect of HCV on HIV disease progression is less clear.Some studies indicate that coinfected people experience slower and...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLM - (BUSINESS WIRE) - The Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the company's business, i.e.to develop therapies for ...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLMThe Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the companys business, i.e.to develop therapies for chronic diseases...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLMThe Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the companys business, i.e.to develop therapies for chronic diseases...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLM--(BUSINESS WIRE)--The Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the companys business, i.e.to develop therapies for ...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
BusinessWire - The Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the company's business, i.e.to develop therapies for chronic...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLM--(BUSINESS WIRE)--The Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the companys business, i.e.to develop therapies for ...
|
|
|
Tripep - Tripep AB changes name to ChronTech Pharma AB
Tripep AB changes name to ChronTech Pharma AB The Annual General Meeting of Tripep AB, held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the companys business, i.e.to develop therapies...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLM--(BUSINESS WIRE)-- (STO: TPEP.ST), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the company?s business, i.e.to develop therapies for chronic diseases. As from...
|
|
|
Tripep AB Changes Name to Chrontech Pharma AB
STOCKHOLM - (Business Wire) The Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the companys business, i.e.to develop therapies for ...
|
